Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Physician-researchers from the Cardiac Center at The Children's Hospital of Philadelphia presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions 2012 in Los Angeles.
Children's National Medical Center is pleased to announce that David L. Wessel, MD, has received the prestigious Meritorious Achievement Award from the American Heart Association (AHA) Council on Cardiovascular Disease of the Young. The award is a national career achievement award recognizing an individual who has made a significant impact in the field of pediatric cardiovascular disease.
US study results indicate that cardiopulmonary exercise is well tolerated, even when performed by individuals with high-risk cardiovascular disease.
Researchers at Boston Children's Hospital have found that microscopic particles containing proteins and nucleic acids called exosomes could potentially protect the fragile lungs of premature babies from serious lung diseases and chronic lung injury caused by inflammation.
Researchers at The Feinstein Institute for Medical Research have discovered that a bean commonly used in Chinese cuisine protects against the life-threatening condition sepsis.
The Feinstein Institute for Medical Research has been awarded a $1 million grant from the World Trade Center Health Program, which is administered by the National Institute for Occupational Safety and Health, part of the US Centers for Disease Control and Prevention, the National Institute for Occupational Safety and Health and Safety to comprehensively study the overall physical, mental and socioeconomic impact of the World Trade Center (WTC) disaster on responders, as well as identify the linkage between socioeconomic status and health among all occupations of WTC responders.
It turns out the muscle cells on the outside of blood vessels have been wrongly accused for instigating lung disease. New research shows that while these muscle cells are responsible for constricting or dilating the blood vessels, they are not responsible for sensing the amount of oxygen that gets to the lungs. That message comes from the endothelial cells - special cells that line the blood vessels - along a "signalling pathway."
Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.
High-resolution computed tomography is useful for the prognosis of patients with systemic scleroderma-related interstitial lung disease, research shows.
Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.
Bayer HealthCare announced today that data on its investigational pulmonary hypertension compound riociguat (BAY 63-2521) will be presented in a scientific forum at the American College of Chest Physicians (ACCP) annual meeting October 20 – 25, in Atlanta, GA.
GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).
GE Healthcare today announced important changes to the U.S. product label for Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the visualization of the left ventricular border - an area of the heart that is critical to see in order to diagnose certain heart diseases such as hypertrophic cardiomyopathy.
Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
The Vanderbilt Heart and Vascular Institute (VHVI) now offers a minimally invasive, catheter-based approach to dissolving pulmonary embolism, a potentially life-threatening blood clot that form elsewhere in the body and travels into the lungs.
As thousands of Americans await a life-saving kidney or liver transplant, medical teams are paying close attention to another organ: their hearts. This month the American Heart Association attempts to bring harmony to the varied cardiac evaluation policies created at U.S. hospitals that assess a patient's overall health before transplant surgery.
Researchers at The Feinstein Institute for Medical Research have discovered that inflammation could be treated by targeting a molecule called the double-stranded RNA dependent protein kinase (PKR). These findings are published in the July issue of Nature.
The UCLA Heart Transplant Program performed its 2,000th heart transplant surgery earlier this month, becoming the first program in the western United States and only the second in the world to achieve this remarkable milestone.
The Zucker Hillside Hospital campus of the Feinstein Institute for Medical Research has been approved for a $9.3+ million federal grant to train clinicians on how to better care for patients with schizophrenia.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.